Emyria Ltd (ASX: EMD) Share Price and News

Mr Tooke is Executive Chairman of Academic Health Solutions, a start-up Group offering advice to clients internationally on medical research and strategy and health service transformation. He is Senior Independent Director at BUPA Chile and was until 2019 non-executive director of the BUPA main Board and the Chair of the Medical Advisory Council. He is the Chair of Collaboration for the Advancement of Sustainable Medical Innovation (CASMI) UCL and Chaired the Oversight Group for the Academy of Medical Sciences project 'How we best use scientific evidence to judge the benefits and harms of medicines'. He also served as an Independent Review Board Member for Google DeepMind Health (UK). Sir John was Head of the School of Life and Medical Sciences at University College London (UCL) as Vice Provost (Health) and Academic Director of UCL Partners from 2010 - 2015. He is the Past President of the Academy of Medical Sciences in the UK. Sir John is a clinician scientist with 30 years' experience as a consultant physician in diabetes, endocrinology, vascular medicine and internal medicine with research experience (basic biomedical, experimental medicine, and applied health research including improvement science) recognised through Fellowship of the Academy of Medical Sciences. He held a Board position at the Francis Crick Institute (2011 - 2015) and was a Member of the Council for Science & Technology (2011-2015) reporting to the Prime Minister (UK).

Mr Winlo. prior to Emyria, Michael was CEO at Linear Clinical Research Ltd (Linear) until October 2019 - a company providing clinical trial services for US- and Asia-based biotech companies. Linear was the first site in Australia and one of only a few in the world to adopt electronic data capture technology. Under Michael's leadership, Linear's revenues grew over 300% in just over three years (to over $23 million per year). Michael retains a Directorship at Linear. Prior to Linear, Michael was Health Lead at Palantir Technologies - a Big Data company based in Silicon Valley California.

Mr Smith is a Biotech/Pharmaceutical Executive, Board Director and Clinical/Scientific Advisor in the US, Europe, Canada and Australia. Her experience covers 50+ clinical trials and 20+ major regulatory approvals in multiple jurisdictions including FDA (USA), EMA (Europe), TGA (Australia), ANVISA (Brazil), and PMDA (Japan); leading to product launches across therapeutic areas including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox, Aczone), neuroscience (Abilify, Solriamfetol), and anti-infectives (Teflaro). In addition to growth and creation of R&D pipelines, Dr Smith's record of business development includes acquisitions, divestitures, and partnership deals. Dr. Smith has held executive roles over the past 20 years, including President, CEO, Global Head of R&D, and Chief Medical Officer. She has built companies from the ground up and is advocate for women in science and diversity in the Boardroom. Earlier in her career, she held senior leadership roles at Allergan, AstraZeneca and Bristol Myers Squibb. Dr. Smith serves on the board of Sangamo Therapeutics (SGMO), Talaris Therapeutics (TALS), and Capstan Therapeutics. Previously, Dr. Smith served on the board of Forward Pharma, Sucampo Pharma, Acceleron Pharma, and Antares Pharma, each with a corporate exit through acquisition. Dr. Smith also holds British and Australian citizenships and is a US Permanent Resident.

Dr Kaushal is a Senior Advisor at General Atlantic, providing strategic support and advice to the firm's investment teams and portfolio companies in the Healthcare sector, drawing on his career in investing, clinical medicine, academia, and public policy. Mohit served as a member of the White House Health IT task force during the Obama Administration and built and led the first dedicated healthcare team at the Federal Communications Commission. He serves on the Food and Drug Administration Safety and Innovation Act Workgroup of the Health IT Policy Committee and the National Committee on Vital and Health Statistics, advising Health and Human Services on data access and use. Mohit is also an ER physician, an Adjunct Professor of Biomedical Data Science at Stanford University and continues to be active within public policy as a Scholar in Residence at the newly created Duke Margolis Center for Health Policy. Earlier in his career, he was a Visiting Scholar at the Brookings Institution.

Mr. Hutchinson's professional background includes the founding and scaling of clinical delivery care models and commercial activities. Mr. Hutchinson co-founded 5D Clinics, a Perth-based radiation oncology business pioneering radiosurgery with CyberKnife technology. Previously, Mr. Hutchinson founded a chain of private physiotherapy clinics across Australia which were eventually acquired by Sonic HealthPlus. Mr. Hutchinson has held leadership roles in rapidly scaling clinical services delivery for over 30 years, spending the last 13 years as the CEO of Sonic HealthPlus and Deputy CEO of Sonic Clinical Services, subsidiaries of Sonic Healthcare Limited an S&P/ASX 100 company.

-

-